The Cancer Council NSW announced funding for a new team at the Kolling Institute to examine a revolutionary approach to treatment for those with acute myeloid leukaemia.
This aggressive form of blood cancer has a tragically poor survival rate, and while we have seen tremendous progress for many other types of cancer in recent years, there have been very limited improvements in treatment for this deadly form of blood cancer.
Internationally respected researcher Dr Jenny Wang will lead the promising new study following the Cancer Council NSW grant of $450,000.
“We are thrilled to have received this generous funding for our project which we hope will lead to an effective, new therapy for this complex cancer,” said the University of Sydney researcher.
“Chemotherapy is currently the first-line treatment for acute myeloid leukaemia.
“There are however, high rates of relapse as this form of cancer is protected by a rare group of cells known as leukaemic stem cells, which have the ability to lay dormant and evade chemotherapy. They then reactivate and renew themselves to drive fresh cancer growth.